Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in ROS1-positive ALK-negative NSCLC (East Asian, China cohort)
CTR20140093Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Sep 2014; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20140093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140093.